Why Arrowhead Pharmaceuticals (ARWR) Is Up 5.9% After First-in-Class Dual Gene RNAi Trial Filing

• Arrowhead Pharmaceuticals recently announced it has filed for regulatory clearance to begin a Phase 1/2a clinical trial of ARO-DIMER-PA, its novel RNAi therapy targeting both PCSK9 and APOC3 genes for potential treatment of mixed hyperlipidemia and atherosclerotic cardiovascular disease.
• This marks a significant innovation for the RNAi field, as ARO-DIMER-PA is the first clinical candidate to simultaneously target two genes in a single molecule using Arrowhead’s TRiM platform.
• We'll see how Arrowhead's move into dual-targeting RNAi therapeutics could reshape its investment outlook and competitive positioning.

Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.

Arrowhead Pharmaceuticals Investment Narrative Recap

Arrowhead Pharmaceuticals appeals to shareholders who believe in the potential of RNA interference technology to address significant unmet needs in cardiometabolic diseases. The recent filing for a Phase 1/2a trial of ARO-DIMER-PA showcases innovation in dual-gene targeting, but its near-term impact on Arrowhead’s largest catalyst, namely, the pivotal Phase III trials and potential launches for plozasiran and zodasiran, is not immediately material, while persistent R&D costs and pending regulatory outcomes remain a key risk to watch.

Among Arrowhead’s recent milestones, the completion of enrollment for multiple pivotal clinical studies for plozasiran stands out. These studies, which target severe hypertriglyceridemia and related cardiovascular risks, represent the most relevant catalyst for near-term shareholder value and may have broader implications for Arrowhead’s ability to advance additional pipeline candidates like ARO-DIMER-PA. Yet, despite growing promise...

Read the full narrative on Arrowhead Pharmaceuticals (it's free!)

Arrowhead Pharmaceuticals' outlook forecasts $398.8 million in revenue and $64.0 million in earnings by 2028. This scenario assumes an annual revenue decline of 11.4% and an earnings increase of $212.4 million from current earnings of -$148.4 million.

Uncover how Arrowhead Pharmaceuticals' forecasts yield a $45.00 fair value, a 18% upside to its current price.

Exploring Other Perspectives

Simply Wall St Community members provided just 2 fair value estimates for Arrowhead Pharmaceuticals ranging from US$0.33 to US$45. Ongoing regulatory and clinical trial uncertainties underscore why opinion on the stock’s outlook can be so widely split among market participants, consider reviewing diverse community research before making your next move.

Explore 2 other fair value estimates on Arrowhead Pharmaceuticals - why the stock might be worth as much as 18% more than the current price!

Build Your Own Arrowhead Pharmaceuticals Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Arrowhead Pharmaceuticals research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Arrowhead Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Arrowhead Pharmaceuticals' overall financial health at a glance.

Interested In Other Possibilities?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Rare earth metals are the new gold rush. Find out which 37 stocks are leading the charge.
• The end of cancer? These 28 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com